Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-02-17FDA Approved: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves a supplemental application for losartan potassium and hydrochlorothiazide from Teva Pharmaceuticals USA, Inc., for this generic…
-
FDA approval · 2017-01-27FDA Approved: LOTREL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Lotrel (amlodipine besylate and benazepril hydrochloride) from Novartis Pharmaceuticals Corp…
-
FDA approval · 2017-01-26FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for hydrochlorothiazide filed by Actavis Pharma, Inc. to update the product labeling.
-
FDA approval · 2017-01-23FDA Approved: CARDIZEM CD — Supplemental Application (Bausch Health US LLC)
The FDA approved a supplemental application for Cardizem CD (diltiazem hydrochloride) from Bausch Health US LLC under NDA 020062, allowing c…
-
FDA approval · 2017-01-11FDA Approved: BISOPROLOL FUMARATE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' Bisoprolol Fumarate (bisoprolol fumarate) via an Original Application; indicated for hypertension and …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-01-05FDA Approved: TRIBENZOR — Supplemental Application (Cosette Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Tribenzor (olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide) from Cosette Ph…
-
FDA approval · 2017-01-05FDA Approved: AZOR — Supplemental Application (Cosette Pharmaceuticals, Inc.)
The FDA approved a supplemental application for AZOR (amlodipine besylate and olmesartan medoxomil) from Cosette Pharmaceuticals, Inc.
-
FDA approval · 2017-01-04FDA Approved: AMLODIPINE BESYLATE — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for amlodipine besylate from Unichem Pharmaceuticals (USA), Inc.
-
FDA approval · 2016-12-15FDA Approved: TELMISARTAN AND HYDROCHLOROTHIAZIDE — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for a generic fixed-dose combination of telmisartan and hydrochlorothiazide for hypertension from Auro…
-
FDA approval · 2016-12-09FDA Approved: AZOR — Supplemental Application (Cosette Pharmaceuticals, Inc.)
FDA issued a supplemental approval for AZOR (amlodipine besylate and olmesartan medoxomil) by Cosette Pharmaceuticals, Inc.
-
FDA approval · 2016-12-06FDA Approved: IRBESARTAN — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's supplemental application for IRBESARTAN, enabling the generic ARB formulation to be marketed …
-
FDA approval · 2016-12-06FDA Approved: IRBESARTAN — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for IRBESARTAN filed by Camber Pharmaceuticals, Inc.
-
FDA approval · 2016-12-02FDA Approved: IRBESARTAN — Supplemental Application (AvKARE)
FDA approved a supplemental application for IRBESARTAN from AvKARE.
-
FDA approval · 2016-11-30FDA Approved: METOPROLOL TARTRATE — Supplemental Application (TRUPHARMA LLC)
FDA approved a supplemental application for metoprolol tartrate submitted by TRUPHARMA LLC. This action approves the supplemental filing for…
-
FDA approval · 2016-11-30FDA Approved: GUANFACINE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma, Inc.'s supplemental application for guanfacine, enabling continued marketing of a generic product. This act…
-
FDA approval · 2016-11-25FDA Approved: METOPROLOL SUCCINATE — Original Application (Actavis Pharma, Inc.)
FDA approved the original application for metoprolol succinate, establishing a generic sustained-release formulation from Actavis Pharma, In…
-
FDA approval · 2016-11-18FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Wilshire Pharmaceuticals, Inc.)
FDA approved a supplemental application for verapamil hydrochloride from Wilshire Pharmaceuticals, Inc., updating the existing NDA.
-
FDA approval · 2016-11-18FDA Approved: DILTIAZEM HYDROCHLORIDE EXTENDED RELEASE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved a supplemental application for Diltiazem hydrochloride extended-release from Oceanside Pharmaceuticals. The product is a calciu…
-
FDA approval · 2016-11-18FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals Inc)
FDA approved a supplemental application for Verapamil hydrochloride from Teva Pharmaceuticals Inc.
-
FDA approval · 2016-11-18FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (EXELA PHARMA SCIENCES, LLC)
The FDA approved a supplemental application for verapamil hydrochloride from Exela Pharma Sciences, LLC.
-
FDA approval · 2016-11-18FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Oceanside Pharmaceuticals)
FDA approved Oceanside Pharmaceuticals' supplemental application for diltiazem hydrochloride. The approval confirms a modification to the pr…
-
FDA approval · 2016-11-18FDA Approved: CARDIZEM CD — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental application for Cardizem CD (diltiazem hydrochloride) submitted by Bausch Health US LLC.
-
FDA approval · 2016-11-17FDA Approved: TELMISARTAN AND AMLODIPINE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's original application for a generic fixed-dose combination tablet of telmisartan and amlodipin…
-
FDA approval · 2016-11-16FDA Approved: LOSARTAN POTASSIUM — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals, Inc.'s supplemental application for Losartan Potassium, marking an approval of changes to the generic pr…
-
FDA approval · 2016-11-08FDA Approved: MATZIM LA — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application for MATZIM LA, a diltiazem hydrochloride product from Actavis Pharma, Inc.